经导管动脉化疗栓塞联合射频消融治疗肝细胞癌患者疗效研究  

One-year survival of patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation combination therapy

作　　者：武向慧 李龙虎 景斐华 武鹏[4] Wu Xianghui;Li Longhu;Jing Feihua(Department of Ultrasonography,Central Hospital,Linfen 041000,Shanxi Province,China)

机构地区：[1]山西省临汾市中心医院超声科,041000 [2]山西省临汾市中心医院介入科,041000 [3]山西省临汾市中心医院影像科,041000 [4]长治医学院附属和济医院超声科

出　　处：《实用肝脏病杂志》2023年第5期702-705,共4页Journal of Practical Hepatology

基　　金：山西省卫生健康委科研计划项目(编号:20200199)。

摘　　要：目的 比较采用经导管肝动脉化疗栓塞(TACE)联合射频消融(RFA)与TACE治疗肝细胞癌(HCC)患者的疗效。方法 2020年2月~2021年4月我院收治的HCC患者60例,其中20例接受TACE联合RFA治疗,另40例接受TACE治疗40例。术后,随访1年。结果 治疗后,TACE联合RFA治疗组完全缓解率、部分缓解率和有效率分别为35.0%、40.0%和75.0%,显著高于TACE治疗组的20.0%、25.0%和45.0%(P<0.05);联合组血清甲胎蛋白水平为(101.4±23.6)μg/L,显著低于TACE治疗组【(364.2±45.6)μg/L,P<0.05】;在TACE或联合RFA治疗后,出现胸腔积液、皮肤灼伤、术后疼痛、一过性血清转氨酶或胆红素轻度升高,均经对症处理后缓解或消失,未出现严重的并发症;TACE联合RFA治疗组1 a生存率为70.0%(14/20),显著高于TACE治疗组的40.0%(16/40),差异具有统计学意义(P<0.05)。结论 采用TACE联合RFA治疗HCC患者有效,能显著提高短期生存率,值得进一步观察。Objective The aim of this study was to investigate the short-term outcomes of patients with hepatocellular carcinoma(HCC)after undergoing transcatheter hepatic arterial chemoembolization(TACE)and radiofrequency ablation(RFA)combination therapy.Methods 60 patients with HCC were encountered in our hospital between February 2020 and April 2021,and out of them,20 patients received TACE and thereafter RFA,and 40 underlying materials-matched patients received TACE alone during the same period.All patients with HCC were followed-up for 12 months.Results After treatment,the complete remission rate,partial remission rate and effectiveness rate in patients having TACE and RFA combination therapy were 35.0%,40.0%and 75.0%,all significantly higher than 20.0%,25.0%and 45.0%(P<0.05)in TACE-treated patients;serum alpha-fetoprotein level in TACE and RFA-treated patients was(101.4±23.6)μg/L,significantly lower than[(364.2±45.6)μg/L,P<0.05]in TACE-treated patients;the common complications after TACE or TACE and RFA combination in our series were pleural effusion,skin burning,local pains and transient serum ALT and/or bilirubin level elevation,all disappeared after appropriate management;the one-year survival rate in TACE and RFA-treated patients was 70.0%(14/20),much higher than 40.0%(16/40)in TACE-treated patients(P<0.05).Conclusion The TACE and RFA combination therapy in the treatment of patients with HCC is efficacious,which might improve the short-term survival,and warrants further clinical investigation.

关 键 词：肝细胞癌 经导管动脉化疗栓塞 射频消融 治疗 

分 类 号：R735.7[医药卫生—肿瘤]